Investee Company News

November 14, 2018 Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results November 12, 2018 Novan Announces Corporate Update Conference Call and Webcast November 7, 2018 Melinta Therapeutics Reports Third Quarter 2018 Financial Results November 5, 2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 October 31, 2018 Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 25, 2018 Novan Creates Dedicated Women’s Health Business Unit October 22, 2018 Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer October 12, 2018 Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan October 5, 2018 Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program October 1, 2018 Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries October 1, 2018 Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November September 25, 2018 Novan Receives FDA Guidance for SB204 and Acne Indication September 21, 2018 Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) September 18, 2018 Melinta Therapeutics Names Peter Milligan as Chief Financial Officer September 7, 2018 Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis September 6, 2018 Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference September 5, 2018 Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma September 5, 2018 Immunocore strengthens IP position in the field of TCR-based therapeutics August 29, 2018 Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference August 29, 2018 Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018 August 20, 2018 Novan Announces Promising Clinical Results with SB414 August 20, 2018 Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours August 8, 2018 Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract August 7, 2018 Melinta Therapeutics Reports Second Quarter 2018 Financial Results August 7, 2018 Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies July 30, 2018 Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases July 20, 2018 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer July 19, 2018 Poseida Therapeutics Appoints John P. Schmid to Board of Directors July 16, 2018 Immunocore Management Change